Terlipressin hits phase III endpoint
admin 16th August 2019 Uncategorised 0CONFIRM is the largest-ever prospective study conducted in patients with hepatorenal syndrome type I. More: Terlipressin hits phase III endpoint Source: News
read more
CONFIRM is the largest-ever prospective study conducted in patients with hepatorenal syndrome type I. More: Terlipressin hits phase III endpoint Source: News
read moreThe Health and Social Care Secretary has announced an evidence-based review into the service. More: Government to reconsider NHS Health Checks Source: News
read moreThe NHS estimates there could be 2,500 fewer emergency admissions to hospital a year for patients with progressive neurological conditions. More: NHS toolkit launched for progressive neurological conditions Source: News
read moreRoche’s targeted cancer drug Rozlytrek officially has its U.S. green light—and in not just one, but two cancer types. Thursday, the FDA cleared the med to treat ROS1-positive non-small cell lung cancer and tough-to-treat NTRK fusion-positive tumors. More: Roche scores
read moreSanofi has been battling against generics companies over patents to Jevtana, its top oncology product. In the latest round, the company scored a win to defend a 2021 patent and a 2031 patent. The company convinced an appeals court to
read morePfizer’s cholesterol fighter Lipitor is the biggest-selling drug of all time, at least for now. But even with $2 billion in annual sales—still growing despite generics—it’s destined to yield its crown to AbbVie’s behemoth Humira. And by 2024, Avastin and
read more© 1994 - 2026 B.M. Pharmaceuticals